Literature DB >> 17314193

Absence of paraneoplastic antineuronal antibodies in sera of 145 patients with motor neuron disease.

Oliver Stich1, Barbara Kleer, Sebastian Rauer.   

Abstract

BACKGROUND: Well characterised antineuronal antibodies (ANAbs) have been shown to be highly specific markers of neurological syndromes with a paraneoplastic aetiology. Previous reports indicate that pure motor neuron disease (MND) is rarely of paraneoplastic origin.
OBJECTIVE: To screen systematically for the prevalence of well characterised paraneoplastic ANAbs in a large collective of patients with pure MND.
METHODS: In a cohort of 145 patients with MND, the frequency of ANAbs was estimated by ELISA, employing recombinant antigens (HuD, Yo, Ri, CV2/CRMP5, Ma2 and amphiphysin).
RESULTS: None of the sera revealed high antineuronal antigen reactivity. Very low reactivity was detected in only five sera, in all probability representing background activity.
CONCLUSION: According to these data, routine analysis for ANAbs in patients with isolated MND is not mandatory.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314193      PMCID: PMC2117733          DOI: 10.1136/jnnp.2006.097774

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Enzyme linked immunosorbent assay using recombinant HuD-autoantigen for serodiagnosis of paraneoplastic neurological syndromes.

Authors:  S Rauer; R Kaiser
Journal:  Acta Neurol Scand       Date:  2001-04       Impact factor: 3.209

3.  Antineural antibodies in the serum of patients with amyotrophic lateral sclerosis.

Authors:  R H Brown; D Johnson; M Ogonowski; H L Weiner
Journal:  Neurology       Date:  1987-01       Impact factor: 9.910

4.  No association of amyotrophic lateral sclerosis with cancer.

Authors:  J Zisfein; J T Caroscio
Journal:  Mt Sinai J Med       Date:  1988-03

5.  Remission of a syndrome indistinguishable from motor neurone disease after resection of bronchial carcinoma.

Authors:  D M Mitchell; S A Olczak
Journal:  Br Med J       Date:  1979-07-21

6.  Motor neurone disease as a manifestation of neoplasm (with a note on the course of classical motor neurone disease).

Authors:  L Brain; P B Croft; M Wilkinson
Journal:  Brain       Date:  1965-09       Impact factor: 13.501

7.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

8.  The spectrum of antineuronal autoantibodies in a series of neurological patients.

Authors:  M Vianello; R Vitaliani; R Pezzani; P Nicolao; C Betterle; G Keir; E J Thompson; B Tavolato; F Scaravilli; B Giometto
Journal:  J Neurol Sci       Date:  2004-05-15       Impact factor: 3.181

9.  Anti-Hu associated paraneoplastic sensory neuronopathy with upper motor neurone involvement.

Authors:  M Ogawa; M Nishie; K Kurahashi; M Kaimori; K Wakabayashi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

10.  Patients with amyotrophic lateral sclerosis and cancer do not differ clinically from patients with sporadic amyotrophic lateral sclerosis.

Authors:  M C Vigliani; P Polo; A Chiò; B Giometto; L Mazzini; D Schiffer
Journal:  J Neurol       Date:  2000-10       Impact factor: 4.849

View more
  1 in total

1.  Cancer and motor neuron disease-causal or coincidental? Two contrasting cases.

Authors:  John Goodfellow; George Gorrie; Veronica Leach; Sameer Patel; Graham Mackay
Journal:  Neurol Sci       Date:  2019-03-06       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.